B
B

Biogen


Notícias

Sage Therapeutics And Biogen Announce FDA Accepts Filing Of New Drug Application And Grants Priority Review Of Zuranolone In The Treatment Of Major Depressive Disorder And Postpartum Depression

BRIEF-Sage Therapeutics And Biogen Announce FDA Accepts Filing Of New Drug Application And Grants Priority Review Of Zuranolone In The Treatment Of Major Depressive Disorder And Postpartum Depression Feb 6 (Reuters) - Biogen Inc BIIB.O : SAGE THERAPEUTICS AND BIOGEN ANNOUNCE FDA ACCEPTS FILING OF NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW OF Z
B
S

Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen

UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen Recasts headline, adds background details throughout Jan 29 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and U.S. biotech firm Biogen Inc BIIB.O said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment.
B

Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen

UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen Recasts headline, adds background details throughout Jan 29 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and U.S. biotech firm Biogen Inc BIIB.O said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment.
B

Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen

Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen Jan 29 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Sunday the Japanese Ministry of Health, Labour and Welfare has given priority review for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of patients
B

Eisai and Biogen Announce Lecanemab Receives Priority Review Status In Japan

BRIEF-BRIEF-Eisai and Biogen Announce Lecanemab Receives Priority Review Status In Japan Jan 29 (Reuters) - Biogen Inc BIIB.O : EISAI CO., LTD. (HEADQUARTERS: TOKYO, CEO: HARUO NAITO, "EISAI") AND BIOGEN INC. (NASDAQ: BIIB, CORPORATE HEADQUARTERS: CAMBRIDGE, MASSACHUSETTS, CEO: CHRISTOPHER A. VIEHBACHER, "BIOGEN") ANNOUNCED TODAY THAT AN APPLICATION FOR MANUFACTURING AND MARKETING APPROVAL FOR LECANEMAB (GENERIC NAME, U.S.
B

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Adds background Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid bet
B

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Adds background Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid bet
B

EU regulator accepts Biogen-Eisai's Alzheimer's treatment lecanemab for review

EU regulator accepts Biogen-Eisai's Alzheimer's treatment lecanemab for review Jan 26 (Reuters) - Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug for review. The drug, lecanemab, was recently granted accelerated approval in the United States.
B

Lonza to buy back $2.17 bln worth of shares, backs mid-term growth

UPDATE 2-Lonza to buy back $2.17 bln worth of shares, backs mid-term growth Adds background on investments, headwinds By Ludwig Burger and Tristan Chabba Jan 25 (Reuters) - Lonza LONN.S on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future.
B
L

Lonza full-year earnings edge market expectations

Lonza full-year earnings edge market expectations Jan 25 (Reuters) - Swiss drug contract manufacturer Lonza LONN.S reported full-year core earnings above expectations, as demand from biopharmaceutical companies remained strong throughout the year. The Basel-based firm reported core EBITDA, or earnings before interest, taxes, depreciation, amortisation and special items, of 2.0 billion Swiss francs ($2.17 billion), up 19.8%.
B
L

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead

UPDATE 1-Eli Lilly Alzheimer's drug setback extends rival Biogen's lead Adds Biogen share movement, background, updates Eli Lilly shares Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's LLY.N Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said.
B

U.S. STOCKS Netflix, PagerDuty, Proterra

BUZZ-U.S. STOCKS ON THE MOVE-Netflix, PagerDuty, Proterra Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq rose on Friday after Netflix kicked off the earnings season for growth stocks on an upbeat note, while Google parent Alphabet gained on news of job cuts.
A
B
B
B
C
D
G
H
N
S
T
U
T
T
U
U
R

U.S. STOCKS Biogen, Wayfair, Costco

BUZZ-U.S. STOCKS ON THE MOVE-Biogen, Wayfair, Costco Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Nasdaq futures rose on Friday, after Netflix kicked off the earnings season for the growth sector on a positive note, but worries about a U.S.
A
B
B
C
D
F
G
H
N
S
T
T
U
R

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's LLY.N Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said. The U.S. Food and Drug Administration (FDA) declined to approve donanemab because Lilly had not submitted data from enough patients who were treated for at least a year, the drugmaker said late Thursda
B

Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug

UPDATE 3-Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug Adds neurologist comments, patient advocacy group comment By Deena Beasley Jan 19 (Reuters) - Eli Lilly and Co LLY.N on Thursday said the U.S. Food and Drug Administration had rejected accelerated approval of its experimental Alzheimer's drug because it had not submitted enough trial data from patients who were treated for at least a year.
B

U.S. STOCKS Apple, Surmodics, Domino's

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Surmodics, Domino's Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes were set to open lower on Thursday as recession worries crept into the foreground of the earnings season, while shares of Procter & Gamble fell as it warned of cost pressures.
A
A
A
B
G
H
J
M
T
T
U
E
R

Eisai files for approval of Alzheimer's drug in Japan

(Updates with background) Jan 16 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen Inc BIIB.O , is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease.
B

Wall St rallies as jobs, services data calm rate hike worries

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * U.S. December payrolls up 223,000 vs est 200,000 * Dec. non-manufacturing PMI 49.6 vs November's 56.5 read * Biogen closes higher as FDA approves Alzheimer's drug * Indexes up: Dow 2.13%, S&P 2.28%, Nasdaq 2.56% By Sinéad Carew and Ankika Biswas Jan 6 (Reuters) - Wall Street's main indexes all gained more than 2% on Friday after December payrolls expanded more than expected even as wag
B
B
C
P
U
U

Wall Street ends sharply higher after Powell comments

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla rises as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * Powell says Fed could scale back rate hikes in December * Indexes end: S&P 500 +3.09%, Nasdaq +4.41%, Dow +2.18% (Updates with detail on S&P 500 moving average, graphics) By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday
A
B
M
N
T
U
U

Wall Street ends sharply higher after Powell comments

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla rises as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * Powell says Fed could scale back rate hikes in December * Indexes end: S&P 500 +3.09%, Nasdaq +4.41%, Dow +2.18% (Updates with details following close of trading session) By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday
A
B
M
N
T
U
U



Condições

Ativos populares

Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.

Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.

Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.

Usamos cookies para lhe dar a melhor experiência no nosso website. Ler mais ou alterar as configurações de cookies.

Aviso de risco: O seu capital está em risco. Os produtos alavancados podem não ser adequados para todos. Recomendamos que consulte a nossa Divulgação de Riscos.